



IDA and Chiltern cement relationship to enable integration of Japan and Asia into global development

Tokyo, Japan, London, U.K. and Wilmington, N.C.; May 31, 2017 — IDA's mission has always been to provide strategic, medical and regulatory consulting together with clinical trial management services to enable the optimal integration of Japan and Asia with global product development.

As you may have heard, on May 31, 2017 IDA was wholly acquired by Chiltern International and henceforth will be known as **"IDA, A Chiltern Company."** As the retention of the IDA name suggests, the management of Chiltern seeks to ensure that first and foremost we remain focused on continuing to provide services in exactly the same manner we have to date. In short, the directive from Chiltern senior management is that it is "business as usual" at IDA.

Of course, what is exciting for the IDA team both near and longer term is that the acquisition by Chiltern enables us to expand our offerings and value to clients by gaining access to Chiltern's therapeutic and regulatory expertise, scientific and operational knowledge, and portfolio of technologies – worldwide. It is particularly meaningful for us that we can expand our services in this manner backed by senior management of Chiltern that is fully supportive of IDA's unique strategic approach to integrated development for Japan and Asia.

Similarly, Chiltern will now have access to IDA's expertise in establishing regulatory and development pathways for Japan and implementing global and pan Asian clinical trials to achieve both Japanese and global regulatory objectives. Together, we can now offer our global customers access to all key markets worldwide, while optimizing product development to maximize speed and efficiency

Please be assured that there will be no change to IDA's client-orientation, project focus and commitment to ensuring success in Japan and Asia. Personally, I am extremely excited about the future and the benefits of this partnership and welcome the chance to discuss this recent news at any time.

Sincerely,

John Winebarger

President & CEO

IDA – A Chiltern Company



To learn more about Chiltern's global clinical development services, visit [Chiltern.com](https://www.chiltern.com).

About Chiltern:

Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern's team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit [Chiltern.com](https://www.chiltern.com) to learn more about how Chiltern is Designed Around You®.